Why Regulus Is Tanking

By Chris Lange Updated Jan 13, 6:17AM EST · Published Jun 28, 9:14AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Regulus Therapeutics Inc. (NASDAQ: RGLS) saw its shares cut in half early Tuesday morning following news of a clinical hold from the U.S. Food and Drug Administration (FDA). The company announced it received verbal notice from the FDA that its Investigational New Drug (IND) RG-101 for the treatment of chronic hepatitis C virus (HCV) infection has been placed on clinical hold.

Ultimately, the company expects it will receive a formal clinical hold letter from the FDA within 30 days and plans to work diligently with the agency to seek the release of the clinical hold.

The agency initiated the clinical hold after Regulus reported a second serious adverse event (SAE) of jaundice. The SAE occurred in a HCV patient with end-stage renal disease on dialysis enrolled in its on-going Phase 1 U.S. study 117 days after receiving a single dose of RG-101.

[nativounit]

Timelines for Regulus’ three on-going studies of RG-101 are not expected to be impacted as all patients have been enrolled and completed their dosing of RG-101 and will continue with protocol scheduled visits. Regulus remains on track to deliver follow-up results from these studies at upcoming relevant scientific meetings.

For some background, Regulus is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkers biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field.

Shares of Regulus closed Monday down 5.3% at $5.01, with a consensus analyst price target of $23.50 and a 52-week trading range of $4.82 to $11.59. Following the announcement, the stock was trading down nearly 50% at $2.68.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.